Impact of Body Composition on Dosimetry of 177Lu-PSMA Radioligand Therapy
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age18+
SponsorCentre Henri Becquerel
About this trial
COCORIVO is an interventional study evaluating the impact of body composition on dosimetry of 177Lu-PSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). Body composition (muscle, lean, visceral fat, subcutaneous fat and total fat masses) will be automatically quantified from whole-body CT images acquired at 72-96h after 177Lu-PSMA injection using the Anthropometer3DNet software. Dosimetry will be evaluated for tumors and organs at risk (salivary glands, bone marrow, kidneys). The study also evaluates the impact of body composition on SUV quantification, the feasibility of single-timepoint dosimetry, and the evolution of body composition during treatment.
Eligibility criteria
Qualifiers
Signed informed consent
Male, age >= 18 years
Histologically confirmed prostatic adenocarcinoma with multidisciplinary decision for 177Lu-PSMA treatment
PSMA expression in tumor lesions confirmed by 68Ga-PSMA PET/CT
Disqualifiers
Patient unable to understand the study or comply with study constraints (language barrier, psychological, geographic...)
Patient under legal protection (tutelle, curatelle, sauvegarde de justice)
Trial design
Treatments tested in this trial
- 177Lu-PSMA-617 + SPECT/CT dosimetry
Treatment groups
100 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov